ECM
MLYS icon

ExodusPoint Capital Management’s Mineralys Therapeutics MLYS Stock Holding History

ExodusPoint Capital Management’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-6,670
Closed -$253K – 1860
2025
Q3 		$253K Sell
6,670
-165,882
-96% -$3.59M ﹤0.01% 1339
2025
Q2 		$2.33M Buy
+172,552
New +$2.5M 0.02% 687
2024
Q3 		– Sell
-274,316
Closed -$3.21M – 1904
2024
Q2 		$3.21M Buy
274,316
+152,110
+124% +$1.92M 0.02% 598
2024
Q1 		$1.58M Buy
122,206
+48,266
+65% +$596K 0.01% 798
2023
Q4 		$636K Sell
73,940
-85,501
-54% -$671K ﹤0.01% 966
2023
Q3 		$1.52M Sell
159,441
-34,084
-18% -$444K 0.01% 788
2023
Q2 		$3.3M Buy
193,525
+12,213
+7% +$183K 0.03% 599
2023
Q1 		$2.84M Buy
+181,312
New +$3.05M 0.02% 742

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

ExodusPoint Capital Management's MLYS Position: Q4 2025 in Review

ExodusPoint Capital Management sold out of Mineralys Therapeutics (MLYS) in Q4 2025, closing a stake of 6,670 shares — an estimated $253K sold.

ExodusPoint Capital Management first reported a position in MLYS in Q1 2023 and held it in 8 quarters. The position peaked at $3.3M in Q2 2023. 223 funds tracked by Wall St. Rank hold MLYS as of Q4 2025.

  • ExodusPoint Capital Management reported no remaining Mineralys Therapeutics position as of Q4 2025 after selling out during the quarter.
  • ExodusPoint Capital Management sold 6,670 Mineralys Therapeutics shares in Q4 2025, an estimated $253K.
  • ExodusPoint Capital Management first reported a position in Mineralys Therapeutics in Q1 2023 and held it in 8 quarters.
  • ExodusPoint Capital Management's Mineralys Therapeutics position peaked at $3.3M in Q2 2023.
  • 223 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q4 2025.

Based on ExodusPoint Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.